| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100763 | Journal of Crohn's and Colitis | 2009 | 9 Pages |
Abstract
Steroids, including budesonide for mild-to-moderate CD, remain the first-line therapy for active luminal CD. Anti-TNFs, in particular IFX as shown by the amount of available evidence, remain the second-line therapy for most indications. Thiopurine analogs, methotrexate and anti-TNFs are favoured in ST-D patients and ST-R patients.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Pierre Michetti, Marc Stelle, Pascal Juillerat, Miquel Gassull, Franz Josef Heil, Eduard Stange, Christian Mottet, Jean-Jacques Gonvers, Valérie Pittet, John-Paul Vader, Florian Froehlich, Christian Felley,